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Because of their genetically determined capacity to respond to pro-inﬂammatory stimuli, keratinocytes have a crucial role in the
pathogenesis of psoriasis. Upon IFN-c and TNF-a exposure, psoriatic keratinocytes express exaggerated levels of inﬂammatory
mediators, andshow aberranthyperproliferation andterminal differentiation.Thethickeningofpsoriasic skinalsoresultsfroma
peculiar resistance of keratinocytes to cytokine-induced apoptosis. In this study, we investigated on the molecular mechanisms
concurringtotheresistanceofpsoriatickeratinocytestocelldeath,focusingontherolehavingsuppressorofcytokinesignaling
(SOCS)1 and SOCS3, two molecules abundantly expressed in IFN-c/TNF-a-activated psoriatic keratinocytes, in sustaining anti-
apoptotic pathways. We found that SOCS1 and SOCS3 suppress cytokine-induced apoptosis by sustaining the activation of the
PI3K/AKT pathway in keratinocytes. The latter determines the activation of the anti-apoptotic NF-jB cascade and, in parallel, the
inhibition of the pro-apoptotic BAD function in keratinocytes. For the ﬁrst time, we report that phosphorylated AKT and
phosphorylated BAD are strongly expressed in lesional psoriatic skin, compared with healthy or not lesional skin, and they
strictly correlate to the high expression of SOCS1 and SOCS3 molecules in the psoriatic epidermis. Finally, the depletion of
SOCS1 and SOCS3, as well as the chemical inactivation of PI3K activity in psoriatic keratinocytes, deﬁnitively unveils the role of
PI3K/AKT cascade on the resistance of diseased keratinocytes to apoptosis.
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Suppressor of cytokine signaling (SOCS) is a family of eight
intracellular proteins (cytokine-inducible Src homology 2-con-
taining protein and SOCS1 to SOCS7), which act as
endogenous inhibitors of pro-inﬂammatory pathways trig-
gered by various cytokines.
1,2 Among these, SOCS1 nega-
tively regulates IFN-g signaling by binding and inactivating
Jak2 protein and, in turn, impeding the activation of STAT1
transcription factor.
3 The inhibitory effect of SOCS1 on IFN-g
signaling has been unequivocally demonstrated in human
keratinocytes, where the ectopic SOCS1 overexpression
determines a reduced production of IFN-g-dependent
genes.
4–7 In addition, SOCS1 is involved in the TNF-a
signaling, as it inhibits TNF-a-induced NF-kB cascade by
decreasing p65 stability within the cell nucleus as well as
ASK1/JNK pathway.
8,9 SOCS3 is another important negative
regulator of cytokine signaling, and it is known to suppress
IL-6 and G-CSF cascades, by directly binding to the speciﬁc
receptors.
10,11 SOCS1 and SOCS3 act not only as anti-
inﬂammatorycheckpointsbutalsoasimportantprotectiveand
pro-survival molecules in various cell types. In particular,
SOCS1 can repress apoptosis induced by TNF-a by sustain-
ing the activation of p38 MAP kinase signaling in murine
ﬁbroblasts or by inhibiting JAK activation in Jurkat T-cell line,
12,13
whereas SOCS3 has been reported to inhibit TNF-a-induced
apoptosis in pancreatic beta cells by impairing the activation of
ERK1/2, p38 and JNK pathways.
14 SOCS3 also suppresses
apoptosis in cancer cells, as demonstrated in renal carcinoma
cells undergoing IFN-a-induced apoptosis.
15
Apoptosis is a form of programmed cell death mediated by
different stimuli, including binding of TNF-a to death TNFR1
receptor. In the continuously renewing skin tissue, mechan-
isms of proliferation, differentiation and cell death are tightly
regulated to prevent inappropriate and excessive epidermal
growth.
16,17 However, dysfunctional apoptosis can occur in
the skin, and it determines the development and chroniciza-
tion of several skin diseases, in particular in psoriasis. In this
pathological context, epidermal keratinocytes are character-
ized by an aberrant resistance to apoptosis, which concurs to
the peculiar thickening of psoriatic epidermis.
18 Multiple
factors have been proposed to contribute to the reduced
susceptibility of keratinocytes to apoptosis, such as their
predisposition to express enhanced levels of the anti-
apoptotic molecules survivin and BCL-XL.
19,20
In this study, we investigated on the molecular mechanisms
involved in rendering psoriatic keratinocytes resistant to cell
death, focusing on the role having SOCS1 and SOCS3
molecules in this context. Firstly, we demonstrated that
SOCS1 and SOCS3 molecules, both abundantly expressed
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www.nature.com/cddisin psoriatic epidermis, suppress the IFN-g/TNF-a-induced
apoptosis in human keratinocytes by speciﬁcally sustaining
the activation of the anti-apoptotic PI3K/AKT pathway. More-
over, we showed that PI3K/AKT activation drives survival
programs in cytokine-activated keratinocytes, by triggering
theanti-apoptoticNF-kBcascadeand,inparallel,byinhibiting
the pro-apoptotic BAD molecule. For the ﬁrst time, in this
study we documented that phosphorylated AKT and phos-
phorylated BAD are strongly expressed in lesional psoriatic
skin, compared with healthy or not lesional skin, and they
strictly correlate to the expression of SOCS molecules in the
psoriatic epidermis. Finally, the depletion of SOCS1 and
SOCS3, similar to the chemical inhibition of PI3K/AKT
pathway in psoriatic keratinocytes, reverts the reduced
susceptibility of these cells to cytokine-induced apoptosis,
deﬁnitively conﬁrming the inﬂuence of this molecular cascade
on the peculiar resistance of diseased keratinocytes to cell
death.
Results
Psoriatic keratinocytes are more predisposed than
healthy cells to express SOCS3 and SOCS1 in response
to IFN-c/TNF-a stimulation. To compare SOCS levels in
healthy and psoriatic keratinocyte strains, we isolated cells
from skin biopsies obtained from psoriatic patients and
healthy donors, and left untreated or stimulated with IFN-g
plus TNF-a for 3h. We found that SOCS3 and SOCS1 mRNA
and protein expression was substantially higher in IFN-g/
TNF-a-activated keratinocytes obtained from psoriatic
patients compared with those isolated from healthy donors
(Figure 1a, Po0.01 and Po0.05 for SOCS3 and SOCS1,
Figure1 IFN-g/TNF-a-inducedSOCS1andSOCS3expressionishigherinpsoriatickeratinocytesthaninhealthycells.(a)Culturedkeratinocyteswerepreparedfromhealthyskin
or from biopsies taken from uninvolved psoriatic skin. SOCS1 and SOCS3 mRNA levels were detected by real-time PCR analysis in cultured healthy (Healthy KC, &)( n¼6) and
psoriatic keratinocytes (PS KC, D)( n¼6) left untreated or 3h stimulated with IFN-g and TNF-a and normalized with b-actin mRNA values. Horizontal lines indicate mean values for
each experimental group. (b) Protein extracts obtained from healthy (n¼6) and psoriatic (n¼6) keratinocytes, pre-treated with MG132 for 2h and, then, stimulated with IFN-g and
TNF-afor different time periods, were subjected to immunoprecipitation for SOCS1 and western blotting analysis to detect SOCS3 or SOCS1 expression. One representative healthy
KCandpsoriaticKCstrainisshown.(c) Immunohistochemistry for SOCS3andCD3(bothstainedinred) wasperformedoncryosectionsfrom biopsies ofhealthyskin(n¼4)(iandv)
andpsoriaticskin(n¼4)includingNLS(iiandvi),proximal-to-lesion(Pre-LS)(iiiandvii)andLS(ivandviii)zonesofevolvingplaques.SectionswerecounterstainedwithMayer’sH&E.
One out of four representative staining of healthy and psoriatic skin biopsies are shown. Values of Po0.05 (*) and Po0.01 (**) were considered signiﬁcant
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Cell Death and Diseaserespectively; Figure 1b). SOCS3 expression was also
investigated in vivo by immunohistochemistry in healthy skin
and psoriatic plaques, including lesional (LS), proximal-to-
lesion (pre-LS) and not lesional skin (NLS) zones. As shown
in Figure 1c, SOCS3 staining was intense throughout the
epidermis of LS psoriasis, with a predominant localization in
the spinosum and granulosum layers (panel iv), and
correlated to the presence in the upper dermis of inﬁltrating
CD3
þ T lymphocytes (panel viii). During the transition from
LS to NLS area of the same skin biopsy, SOCS3
immunoreactivity decreased in the epidermal compartment,
concomitantly to the reduced number of inﬁltrating T cells
(panels iii and vii). Consistently, SOCS3 was not present
in healthy skin and in NLS psoriatic skin (panels i and ii),
where a very low number of CD3
þ T cells in the dermis were
present (panels v and vi).
SOCS3 and SOCS1 suppress cytokine-induced apoptosis
in human keratinocytes. SOCS1 and SOCS3 have been
described as anti-inﬂammatory molecules able also to
suppress apoptosis induced by different stimuli.
1,12,14 To
investigate whether SOCS1 and/or SOCS3 can protect
human keratinocytes from cytokine-induced cell death, we
treated Myc-SOCS1 or -SOCS3-overexpressing HaCaT
clones for 48h with TNF-a, a potent cytokine inducer of
keratinocyte apoptosis, and examined their apoptosis rate by
measuring annexin staining and PI incorporation (Figure 2a).
SOCS2 clones were analyzed to determine whether other
SOCS family members provided resistance against TNF-a-
induced cell death. Contrarily to SOCS2, SOCS1 (Po0.05)
and, more signiﬁcantly, SOCS3 clones (Po0.01) showed an
enhanced resistance to TNF-a-induced apoptosis compared
with MOCK clones (Figure 2a). Also the expression of active
caspase 9, a mediator of apoptosis triggered by TNF-a, was
reduced in SOCS3 and SOCS1 compared with activated
MOCK or SOCS2 clones (Figure 2a). As expected, SOCS1-
and, more efﬁciently, SOCS3-silenced keratinocytes resulted
to be more susceptible to IFN-g/TNF-a-induced apoptosis
compared with cells transfected with irrelevant siRNA
(Figure 2b, Po0.01 for SOCS3, and Po0.05 for SOCS1).
Taken together, these ﬁndings reveal that SOCS1 and, more
efﬁciently, SOCS3 protect human keratinocytes from cyto-
kine-induced death.
SOCS3 and SOCS1 sustain RAS/AKT cascade, which
counteracts cytokine-induced apoptosis in keratino-
cytes. SOCS1 contributes to the induction of RAS and
downstream ERK1/2, a pro-survival cascade protecting
keratinocytes from the detrimental effects of pro-inﬂamma-
tory cytokines.
5 As the anti-apoptotic PI3K/AKT pathway is
also a crucial effector of RAS,
21,22 we analyzed whether
SOCS1 and SOCS3 could sustain AKT activation, and
whether this activation, in turn, could protect keratinocytes
from the TNF-a-induced apoptosis. Firstly, contrarily to
MOCK and SOCS2 clones, SOCS1 and SOCS3 strains
showed a relevant basal activation of RAS, while it was
drastically reduced in SOCS3- and in SOCS1-silenced cells
upon IFN-g/TNF-a-treatment (Figure 3a, Po0.01 for SOCS3
and Po0.05 for SOCS1), as compared with control
keratinocytes. In addition, SOCS1 and, more efﬁciently,
SOCS3 supported AKT phosphorylation in serine 473, as
demonstrated in SOCS-overexpressing clones and in
SOCS3- or SOCS1-depleted keratinocytes treated with
IFN-g and TNF-a (Figure 3b). In a next series of experiments,
we showed that, when treated with increasing doses of the
chemical PI3K inhibitor, Ly29, the susceptibility of SOCS1
and SOCS3 clones to TNF-a-induced death increased,
differently from what was observed for MOCK or SOCS2
cells (Figure 4a). Ly29 effect reverting the anti-apoptotic
SOCS1 and SOCS3 function was speciﬁc, as other chemical
inhibitors, such as the JAK2 inhibitor AG490 or the ERK1/2
inhibitor PD98059, had null or only slight effect on TNF-a-
induced apoptosis (Figure 4b). Therefore, PI3K/AKT path-
way sustained by SOCS3 and SOCS1 speciﬁcally protects
keratinocytes from cytokine-induced death.
AKT activation by IFN-c/TNF-a triggers NF-jB cascade
and, in parallel, induces phosphorylation and inactiva-
tion of BAD in human keratinocytes. AKT activation
occurs in IFN-g/TNF-a-treated keratinocytes with delayed
kinetics, being its phosphorylation substantially upregulated
12–24h after stimulation (Figure 5a). As human keratinocytes
exposed to UV radiation show protective AKT-mediated
programs involving NF-kB and the pro-apoptotic BAD
molecule,
23,24 we analyzed the NF-kB and BAD cascades in
keratinocyte cultures pre-treated with Ly29 and stimulated
with IFN-g plus TNF-a. AKT inhibition determined a massive
accumulation of IkBa protein, the endogenous inhibitor of NF-
kB family, and the decrease of the phosphorylated p65
(Ser276) factor (Figure 5b). As a possible consequence of NF-
kB downregulation by PI3K/AKT inhibition, we found a quite
totally compromised expression of the anti-apoptotic BCL-2
protein, a well-known NF-kB transcriptional target
25
(Figure 5b). Contrarily, the expression of BCL-XL, another
pro-survival molecule known to be activated by NF-kB
pathway, was not affected by the inhibition of AKT activity.
However, BCL-XL fraction associated to the pro-apoptotic
p-BAD molecule, barely detectable in cells not treated with
Ly29, increased following Ly29 treatment, concomitantly to a
signiﬁcant reduction of phosphorylated BAD, an inactive form
of BAD (Figure 5b). Therefore, AKT activation by IFN-g/TNF-a
in human keratinocytes executes anti-apoptotic functions by
activating the pro-survival NF-kB cascade and, in parallel, by
inducing BAD phosphorylation/inactivation and dissociation
from the anti-apoptotic BCL-XL molecule.
Phospho-AKT, phospho-BAD and BCL-XL are strongly
expressed in activated psoriatic keratinocytes. The
hyperplasia of the psoriatic epidermis is in part due to a
peculiar resistance of psoriatic keratinocytes to apoptotic
stimuli compared with healthy cells.
26–29 As we showed that
AKT signaling can trigger survival signals in IFN-g/TNF-a-
activated keratinocytes, we sought to analyze whether
phosphorylated AKT and downstream phosphorylated p65,
phosphorylated BAD and BCL-XL anti-apoptotic molecules
could be upregulated in psoriatic skin in vivo and in
keratinocyte strains isolated from skin of psoriatic patients.
Phospho-AKT (Ser473) staining was intense in the spinosum
and granulosum layers of LS psoriatic epidermis, whereas it
was quite absent in NLS area of the same biopsies and in
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Cell Death and Diseasehealthy epidermis (Figure 6a). Also phospho-p65, phospho
BAD and BCL-XL expression was higher compared with
healthy and NLS psoriatic skin, and mainly localized in
the upper layers of the psoriatic epidermis (Figure 6a).
Consistently with the in vivo analysis, cultured psoriatic
strains were more prone than healthy cells to express
enhanced levels of phospho-AKT in response to cytokine
treatment (Figure 6b). Therefore, AKT staining in psoriatic
epidermis ﬁts with the downstream anti-apoptotic phospho-
p65, phospho-BAD and BCL-XL molecules, in terms not only
of expression levels but also of localization within the
psoriatic epidermal compartment.
SOCS3 and SOCS1 overexpression in activated
psoriatic keratinocytes contributes to their peculiar
resistance to cytokine-induced apoptosis. Finally, we
investigated whether SOCS3 and SOCS1 participated to the
reduced sensitivity of psoriatic keratinocytes to cytokine-
induced death. Firstly, we assessed that the apoptotic rate of
cultured psoriatic keratinocytes in response to IFN-g and
Figure 2 Cytokine-induced apoptosis in human keratinocytes is suppressed by SOCS1 and SOCS3 molecules. (a) HaCaT cells were stably transfected with myc-tagged
socs1,socs2andsocs3genesorcontrolplasmids.MOCK(’,n¼6),SOCS1(m,n¼6),SOCS2(.,n¼6)andSOCS3(K,n¼6)cloneswereleftuntreatedorstimulated
with TNF-a for 48h and their apoptosis was examined by measuring Annexin/PI ﬂuorescent staining or expression of active caspase 9 through FACS analysis. Data were
expressed as F.I. between TNF-a-treated samples and untreated samples, to which a value of 1 was given. Ectopic SOCS1, SOCS2 and SOCS3 expression in different
clones was determined by immunoblotting with an anti-c-myc Ab. (b) Transient RNA interference was performed by transfecting cultured healthy keratinocytes with SOCS1,
SOCS3 or irrelevant (NC) siRNA, and then by treating cells with IFN-g/TNF-a for 48h. Apoptosis was evaluated as described in (a). SOCS1 and SOCS3 mRNA levels in
siRNA-transfected cells were measured by real-time PCR. SOCS3 mRNA levels were monitored to validate the speciﬁcity of SOCS1 siRNA, and vice versa. All data were
obtained from three independent experiments of RNA interference. Values of Po0.05 (*) and Po0.01 (**) were considered signiﬁcant
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Cell Death and DiseaseTNF-a treatments was signiﬁcantly lower than that of healthy
strains (4 three times decrement in psoriatic cells, Po0.01)
(Figure 7a). However, when SOCS3 or SOCS1 mRNA were
silenced by transient treatment of cultures with speciﬁc
siRNA, psoriatic keratinocytes strains became more suscep-
tible to apoptosis induced by IFN-g and TNF-a treatments
(Figure 7b). Similar effects were observed when cultured
psoriatic keratinocytes were treated with increasing doses of
Figure 3 SOCS3 and SOCS1 participate to the induction of RAS activation and AKT phosphorylation in cytokine-activated keratinocytes. (a) RAS activity was measured
on lysates obtained from MOCK (n¼2), SOCS1 (n¼4), SOCS2 (n¼2) and SOCS3 (n¼6) keratinocyte clones treated with TNF-a for 3h. GTP-bound RAS was pulled-
downusing Raf-1RBD agaroseas substrateand detectedby WB with an anti-RASAb. RAS activity was also analyzedin SOCS1-or SOCS3-interfered keratinocytes treated
with IFN-g/TNF-a for 12 or 24h and compared with that observed in NC-transfected cells. Data are expressed as F.I.±S.D. between IFN-g/TNF-a time-course points and
untreatedsamples(time0),towhichavalueof1weregiven.(b)PhosphorylationofAKTinSer473wasevaluatedby immunoblottingonproteinlysatesobtainedfromMOCK
and SOCS clones treated with TNF-a for 6h, and from SOCS1-or SOCS3-silenced keratinocytes stimulated with IFN-g/TNF-a for 18 or 36h. Filters were stripped and
re-probed with an anti-AKT Ab. In RNA interference experiments, F.I. values relative to SOCS1 or SOCS3-silenced keratinocytes were compared with those obtained from
NC-interfered cells. In RNA interference experiments, data were obtained by three independent experiments. Values of Po0.05 (*) and Po0.01 (**) were considered
signiﬁcant
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Cell Death and DiseaseLy29 (Figure 7c). Although the chemical inhibition of PI3K/
AKT signaling enhanced apoptosis in both healthy and
psoriatic cells, this effect was more evident in psoriatic
strains (Figure 7c; Po0.05 and Po0.01 for healthy and
psoriatic, respectively), suggesting a functional link between
PI3K/AKT pathway, sustained by SOCS1 and SOCS3, and
the peculiar resistance of psoriatic keratinocytes to cytokine-
induced apoptosis.
Discussion
Psoriasis is an immune-mediated skin disease driven by
memory-effector, skin-homing T cells. In psoriatic skin
lesions, T cells locally release pro-inﬂammatory cytokines,
such as IFN-g and TNF-a, responsible for the activation of the
resident epidermal keratinocytes skin.
26,30 Because of their
intrinsically altered capacity to respond to IFN-g and
Figure 4 Inhibition of PI3K/AKT pathway, but not of JAK2, in SOCS1 and SOCS3 clones increases their sensitivity to TNF-a-induced apoptosis. (a) SOCS1 (m, n¼6)
andSOCS3(K,n¼6)clones,togetherwithMOCK(’,n¼6)andSOCS2(.,n¼6)clonesusedascontrol,werepre-incubatedornotwithincreasingdoses(3and15mM
ﬁnal concentration) of the chemical PI3K inhibitor, Ly294002, and then left untreated or stimulated with TNF-a for 48h. (b) Similarly, MOCK 1.1, SOCS1 1.4, SOCS2 3.1 and
SOCS36.6 cloneswere pre-treated or notwith increasing doses(from 5 to 30mM) of PD98059(ERK1/2 inhibitor)or AG490(JAK2 inhibitor),and then stimulatedwith TNF-a.
Inall experiments,apoptosiswas evaluatedby measuringAnnexin/PIﬂuorescent staining.Dataare expressedas F.I. betweenTNF-a-treatedcellsand untreatedsamples, to
which a value of 1 was given. Values of Po0.05 (*) and Po0.01 (**) were considered signiﬁcant
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Cell Death and DiseaseTNF-a, psoriatic keratinocytes express a plethora of inﬂam-
matory mediators, involved in the chronicization of the local
immune responses.
26,31 Additionally, psoriatic keratinocytes
exhibit a marked hyper-proliferation and an incomplete
terminal differentiation in response to mitogenic signals and
are characterized by an aberrant resistance to apoptosis,
which synergistically contribute to the peculiar epidermal
thickening of diseased skin.
18,26,32,33 Although many efforts
have been made to elucidate the mechanisms responsible for
the alterations in psoriatic epidermis of proliferation and
differentiation programs,
34,35 to date limited information exist
on the processes concurring to the reduced susceptibility of
affected keratinocytes to cytokine-induced apoptosis. In this
study, we have investigated on the involvement of SOCS3
and SOCS1 molecules in protecting psoriatic keratinocytes
from IFN-g/TNF-a-induced cell death. This interest arose from
previous observations that SOCS1 has been described as an
anti-apoptotic molecules, and that psoriatic keratinocytes
express enhanced levels of SOCS1 compared with healthy
cells.
6,12,13 We extended our analysis to SOCS3 molecule,
whose expression is highly induced by IFN-g and TNF-a,
unveiling that activated psoriatic keratinocyte cultures have a
particular attitude to upregulate SOCS3, other than SOCS1,
as compared with healthy cells. In fact, SOCS3 highly
accumulated in vivo in psoriasis plaques, but, differently from
SOCS1 mainly detected in the basal and spinosum layers of
epidermis,
6 it abundantly localized in the upper stratum of the
epidermis. The abnormal SOCS1 expression in psoriatic
keratinocytes depended on an alteration of the transcriptional
machinery regulating its promoter function, involving growth
factorindependence-1bandKruppel-likefactor4transcription
factors.
6 Aimed at correlating the high SOCS3 and SOCS1
expression to the resistance to apoptosis of psoriatic
keratinocytes,wemanipulatedtheirexpressionandevaluated
the effects on cytokine-induced cell death. In both experi-
mental conditions, SOCS1 and, more markedly, SOCS3
could suppress the IFN-g/TNF-a-induced apoptosis in human
keratinocytes. Although we show here for the ﬁrst time that
SOCS3 and SOCS1 confer resistance to cytokine-induced
apoptosis to keratinocytes, this SOCS function has been
described in the past for other cell types, including ﬁbroblasts
and pancreatic cells.
12–14 In these cell systems, the mechan-
isms underlying the SOCS1 and SOCS3 inhibition of
apoptosis involved the activation of RAS-dependent ERK1/
2, p38 and JNK signalings.
12,14 In our study, we could
demonstrate that SOCS1 and, at a higher extent, SOCS3,
transiently induced by IFN-g plus TNF-a, could protect
keratinocytes from apoptosis by sustaining another RAS-
dependent pathway, in particular the PI3K/AKT cascade. This
pathway speciﬁcally protected keratinocytes from apoptosis,
since the inhibition of JAK2 activity in SOCS1 and SOCS3
keratinocyte clones did not affect their apoptotic rates. The
slight increase of TNF-a-induced apoptosis determined by
ERK1/2 inhibitor PD98059 in SOCS1 and SOCS3 clones
conﬁrmed the protective and pro-survival role of ERK1/2 in
human keratinocytes.
5 However, differently from ERK1/2
cascade, linked to the regulation of anti-inﬂammatory and
proliferative programs following cytokine exposure, PI3K/AKT
pathway seems to be implicated in mechanisms aimed at
rescuing keratinocytes from apoptosis. This has been
demonstrated in keratinocytes exposed to UV, which show
reduced apoptosis subsequently to a downregulation of
the intracellular pro-apoptotic factors BAD, IKBa and
GSK3.
23,24,36
Concerning the AKT downstream effects in keratinocytes,
we found that this anti-apoptotic pathway determined the
activation of NF-kB and, in parallel, the inhibition of the pro-
apoptotic function of BAD. It is known that NF-kB pathway
protects a number of cell types from apoptosis by inducing the
expression of anti-apoptotic proteins, including survivin,
FLICE-like inhibitory protein and members of the inhibitor of
apoptosis family, such as BCL-2 molecule.
37–39 Accordingly
to these studies, we demonstrated that BCL-2 expression is
positively regulatedby PI3K-AKT pathway, possibly through a
direct action of NF-kB induced by pro-inﬂammatory cytokines
in human keratinocytes.
In relation to the role of BAD molecule, it has been reported
that in UVB-irradiated keratinocytes, AKT-induced phosphor-
ylation of BAD determines its inactivation and its release from
BCL-XL.
24 This event results in the suppression of pro-
apoptotic mechanisms, by directly interfering with BAX/BAK-
induced mitochondrial permeabilization.
24 In light of this
knowledge, it is reasonable to suppose that NF-kB activation
and BAD inhibition contribute to re-establishment of survival
and protective programs also when apoptosis is induced by
pro-inﬂammatory cytokines.
Interestingly, the expression of phosphorylated AKT was
intense in lesional psoriatic skin, and paralleled the presence
of an abundant CD3
þ T-cell inﬁltrate. Contrarily, healthy and
Figure 5 AKT phosphorylation determines the activation of NF-kB cascade
and, in parallel, the phosphorylation and inhibition of BAD molecule. (a) AKT
phosphorylation (Ser473) was monitored in keratinocytes treatedwith IFN-g/TNF-a
at different time points by WB analysis. Filters were stripped and re-probed with an
anti-AKT Ab. (b) Primary human keratinocytes were pre-treated with Ly294002
(15mM) for 2h and then stimulated with IFN-g/TNF-a for 12h. In left panel, protein
extracts were subjected to WB with anti-phospho AKT (Ser473), anti-AKT, anti-
IkBa, anti-phospho p65 (Ser 276), anti-BCL-2, anti-BCL-XL and anti-b-actin Abs.
In right panels, co-immunoprecipitation of endogenous phospho-BAD (Ser136)
was followed by WB using anti-BCL-XL Ab. Filter was stripped and re-probed with
BAD Ab
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Cell Death and DiseaseNLS psoriatic skin exhibited a similar expression of phos-
phorylated AKT, indicating that the enhanced AKT expression
in lesional plaques was the consequence of the microenviro-
mental cytokine milieu. However, in vitro activation of AKT
was more evident in psoriatic keratinocyte strains compared
with the healthy ones, indicating again that psoriatic cells are
more responsive to cytokine stimulations. Consistently with
AKT in vivo distribution, the expression of phospho-BAD and
BCL-XL in psoriatic skin was intense and accumulated in the
upper layers of psoriatic epidermis. The ﬁndings that SOCS3
co-localized with phospho-AKT, phospho-BAD and BCL-XL
molecules in the same epidermal compartments suggest their
possible cross regulation in vivo. Interestingly, together with
other apoptosis-related proteins, BCL-2 has also been
detected in the epidermis of skin affected by psoriasis, and
found to be reduced in lesional keratinocytes after treatment
with TNF-a-targeting agents.
25
The evidence that SOCS1 and SOCS3 render psoriatic
keratinocytes resistant to apoptosis comes from SOCS1 and
SOCS3 mRNA knocking-down experiments in these cell
strains, where the IFN-g plus TNF-a-induced apoptosis were
efﬁciently inhibited. The chemical inhibition of PI3K/AKT
cascade also reverted the capability of psoriatic keratinocytes
to resist to pro-apoptotic stimuli. Further experiments aimed
at rescuing the resistance to IFN-g/TNF-a-induced death
through the ectopic overexpression of AKT gene in SOCS1- or
Figure 6 Expression of phospho-AKT, phospho-p65, phospho-BAD and BCL-XL is upregulated in activated psoriatic keratinocytes. (a) Immunohistochemistry for p-AKT
(Ser473)andp-BAD(Ser136)wereperformedonfrozensectionsfrombiopsiesofhealthy(n¼4)andpsoriatic(n¼4)skin,includingNLSandLSareasofplaques.Phospho-
p65andBCL-XLin vivostainingwas performedon parafﬁn-embeddedsectionsof healthy,NL andLSskinbiopsies.Sectionswerecounterstained with Mayer’sH&E. Oneout
offourrepresentativestainingofpsoriaticskinisshown.(b)Phospho-AKT(Ser473)levelwasdetectedinproteinlysatesofculturedhealthyandpsoriatickeratinocytestreated
with IFN-g/TNF-a for 12h. Filter was stripped and re-probed with anti-AKT Ab. One out of six representative healthy and psoriatic keratinocyte strains is shown
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Cell Death and DiseaseSOCS3-depletedpsoriatic keratinocyteswill deﬁnitelyconﬁrm
the functional link between SOCS1 and SOCS3 and AKT-
mediated apoptosis, typically impaired in psoriatic cells.
In conclusion, this study demonstrated that the strong
upregulation of SOCS1 and SOCS3 in activated psoriatic
keratinocytes concurs in reducing apoptosis induced by pro-
inﬂammatory cytokines in these cells. The higher SOCS1 and
SOCS3 expression in psoriatic keratinocytes compared with
healthy cells likely could represent a mechanism by which
psoriatic cells protect themselves from exaggerated and
repeated stimulation by IFN-g and TNF-a (Supplementary
Figure) occurring in active skin lesions. On the other hand, the
enhanced SOCS1 and SOCS3 expression could have side
effects, concurring at reducing susceptibility to IFN-g/TNF-a-
effects, expressed not only in terms of pro-inﬂammatory gene
expression but also of apoptosis induction. The enhanced
SOCS1 and SOCS3 expression in psoriatic keratinocytes
could ultimately contribute to the expression of the peculiar
epidermal thickening of psoriatic skin (Supplementary Figure).
In light of our ﬁndings, the use ofinhibitors of PI3K/AKT axis
in epidermal keratinocytes may be therapeutically relevant for
the treatment of psoriasis, but also for other skin diseases
characterized by a deﬁcient keratinocyte apoptosis, including
non-melanoma skin cancers.
40 Further studies using chemi-
cal AKT inhibitors in experimental models of psoriasis in vitro
and in vivo should better deﬁne the role of the anti-apoptotic
programs in the psoriatic epidermal thickening.
Materials and Methods
Subjects. Ten patients with severe chronic plaque psoriasis were included in
this study. Among these patients, four were selected for immunohistochemical
studies and six to establish keratinocyte cultures. Patients had deﬁnite psoriasis
diagnosed according to standard criteria, and they had not received any systemic
or topical therapy for at least 1 month before skin donation. Skin was also obtained
from ten healthy subjects undergoing plastic surgery.
Keratinocyte cultures and treatments. Normal human keratinocytes
were obtained from skin biopsies of healthy volunteers or psoriatic patients and
cultured, as previously reported.
5,6 Stimulations with 200U/ml human recombinant
IFN-g (R&D Systems, Minneapolis, MN, USA) and 50ng/ml human recombinant
TNF-a, as well as treatments with the chemical Ly294002 or MG132 inhibitors
(Calbiochem, Gibbstown, NJ, USA), were performed in keratinocyte basal medium
(Clonetics, Walkersville, MD, USA). The HaCaT human keratinocyte cell line (NE
Fusenig, Deutsches Krebsforschungszentrum, Heidelberg, Germany) was grown
and stimulated as previously described.
4,5
Permanent transfections. HaCaT cells were stably transfected with
myc/SOCS1, myc/SOCS2, myc/SOCS3 or empty pcDNA3 plasmids as previously
reported.
4,5 When indicated, HaCaT clones were treated with the chemical
inhibitors Ly29, PD98059 or AG490 (Calbiochem) in DMEM.
RNA Isolation and Real time RT-PCR. Total RNA isolation and real-time
RT-PCR analyses for SOCS1 and SOCS3 mRNA expression were performed as
previously described.
5,6 Fluorescence intensity was analyzed by the ABI PRISM
SDS 7000 PCR Instrument (Applied Biosystems, Branchburg, NJ, USA). The fold-
induction value for triplicate wells was averaged, and data were presented as the
mean±S.D.
Immunoprecipitation, immunoblotting and densitometry. Protein
extract preparation, immunoprecipitation and immunoblotting were performed
accordingly to standard procedures.
5,6 The Abs used for the study were as follows:
anti-SOCS1 and anti-SOCS3 (MBL International Corporation, Nakaku Nagoya,
Japan), anti-phospho-p65 (Ser276), anti-IkBa, HRP-conjugated anti-c-myc
(9E10), anti-b-actin (all from Santa Cruz Biotechnology, Santa Cruz, CA, USA)
Figure 7 SOCS1 and SOCS3 depletion, as well as the chemical inhibition of
PI3K/AKT axis, in activated psoriatic keratinocytes revert their resistance to IFN-g/
TNF-a-induced cell death. (a) Cultured healthy (&, n¼6) and psoriatic (n, n¼6)
keratinocytes were left untreated or treated with IFN-g/TNF-a for 48h. (b) Cultured
psoriatic keratinocytes (n¼6) were transfected with increasing doses of SOCS1
plus SOCS3 siRNA (n) or irrelevant siRNA (m) (20 and 80nM), then left untreated
or treated with IFN-g/TNF-a for 48h. (c) Cultured healthy (&, n¼6) and psoriatic
(n, n¼6) keratinocytes were pre-incubated with increasing doses of Ly294002
(15 and 25mM) for 2h and then left untreated or treated with IFN-g/TNF-a
for 48h. In all experiments, apoptosis was evaluated by measuring Annexin/PI
ﬂuorescentstaining.DatawereexpressedasratiobetweenTNF-a-treatedcellsand
untreated samples. Values of Po0.05 (*) and Po0.01 (**) were considered
signiﬁcant
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Cell Death and Diseaseand anti-phospho-AKT (Ser473), anti-AKT, anti-phospho-BAD (Ser136) and anti-
BAD (all from Cell Signaling, Danvers, MA, USA). Anti-BCL-XL was purchased
from Calbiochem (La Jolla, CA, USA). Immunoblots of experiments evaluating
phospho-AKT and GTP-RAS levels were subjected to densitometry using an
Imaging Densitometer model GS-670 (Bio-Rad, Hercules, CA, USA) supported by
the Molecular Analyst software (Bio-Rad), and band intensities were evaluated in
three independent experiments. Data are expressed as fold-induction (F.I.)±S.D.
in experimental IFN-g/TNF-a time-course relative to untreated samples, to which
were given a value of 1.
Transient RNA interference. SOCS1 or SOCS3 were knocked down in
keratinocyte cultures as previously described.
5,6 SOCS1 (L-011511-00-0005),
SOCS3 (L-004299-00-0005) or irrelevant (L-011511-00-0005) pool of four small
siRNA (Dharmacon RNA Technology, Lafayette, CO, USA) were used at a ﬁnal
concentration ranging from 20 to 80nM. After 24h of transfection, cells were
stimulated with IFN-g and TNF-a for the indicated time periods.
In vitro kinase assays. RAS activation assays was performed using
commercial kit from Upstate (Upstate Biotechnologies, Temecula, CA, USA),
according to manufacturer’ instructions.
Apoptosis analysis. Apoptosis of keratinocytes was evaluated using the
Genzyme TACS Annexin V apoptosis detection kit (R&D Systems) or using the
carboxyﬂuorescein FLICA assay kit (B-Bridge International, Sunnyvale, CA, USA).
Viable, necrotic and apoptotic were analyzed by ﬂow cytometry. Cells were
analyzed with a FACScan equipped with Cell Quest software (Becton Dickinson,
Mountain View, CA, USA). Data were expressed as F.I. between cytokine-treated
and untreated samples, to which a value of 1 was given.
Immunohistochemistry. Parafﬁn-embedded sections or cryostatic sections
were obtained from biopsies of psoriatic skin including LS, Pre-LS and NLS zones
of evolving plaques as well as healthy skin. Parafﬁn-embedded sections were
incubated with Abs against BCL-XL (Calbiochem) or phospho-p65 (Cell Signaling).
Cryostatic sections were incubated with anti-SOCS3 (MBL), -CD3 (BD), -p-AKT
(Cell Signaling) and -p-BAD (Cell Signaling) Abs. Secondary biotinylated mAbs
and staining kits (Vector Laboratories, Burlinagame, CA, USA) were used to
develop immunoreactivities.
Statistical analysis. Statistical signiﬁcance was evaluated using Wilcoxon’s
signed rank test (SigmaStat; Jandel, San Rafael, CA, USA). Values of Pr0.05
were considered signiﬁcant.
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